As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

United States Vaccine Market: By Technology: Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

United States Vaccine Market Outlook

The United States vaccine market attained a value of about USD 11.2 billion in 2020. The market is further expected to grow in the forecast period of 2021-2026 at a CAGR of 9.8%.

 

Increasing Deployment of mRNA Technology in Vaccine Development is Aiding the Market Growth

The initiation of vaccine development through mRNA technology is increasing research and development (R&D) activities owing to the prevalence of various infectious diseases, such as Ebola, Zika, and influenza, among others. This trend has been fuelled due to the emergence of SARS-CoV-2, which is surging the requirement for effective vaccines to prevent morbidity and fatality, which has driven the market.

 

United States Vaccine Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

As research activities to develop efficient vaccines were initiated, mRNA technology was leveraged to easily modify the sequencing of vaccines to enable their effectiveness against the mutations of the novel virus, which has driven the market growth. Moreover, the development of mRNA vaccines against COVID-19 infections by leading companies, such as Pfizer and Moderna, has fuelled the market growth. The increasing approvals of the novel COVID-19 mRNA vaccines have provided further impetus to the market growth. For instance, the Food and Drug Administration of the United States authorised the emergency use of Pfizer’s mRNA vaccine, BNT162b2, in December 2020.

 

Vaccine: Industry Definition and Segmentation

A vaccine is a medicine that enables the suspension of killed or weakened microbes to enable the development of antibodies and prevent the risk of contraction of infectious disease. It provides active immunity from diseases to enhance the quality of life. The administration of vaccines, variously known as vaccination, is one of the most effective ways to prevent the spread of infectious diseases.

The major technologies of vaccine are:

  • Recombinant and Conjugate Vaccine
  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Others

The market can be broadly categorised on the basis of its indications into:

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella, Measles, Mumps, and Rubella
  • Diphtheria, Pertussis, and Tetanus (DPT)
  • Polio
  • Hepatitis
  • Others

By end uses, the market is divided into:

  • Paediatric Vaccine
  • Adult Vaccine
  • Travellers Vaccine

The EMR report looks into the regional markets of vaccine in the United States like New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West.

 

Rising Demand for Immunisation of Infants to Bolster the Market Growth of Vaccine in the United States

The rising demand for vaccines of pathogenic issues, diarrhoeal diseases, and parasitic adversaries, among others, is augmenting the industry growth. As the requirement of immunisation of infants to enhance the quality of life is surging, vaccines are increasingly deployed to prevent the risk of infectious diseases among children, hence fuelling the market growth. For instance, federally funded programs such as the Vaccines for Children (VFC) and Children’s Health Insurance Program (CHIP) offers free vaccination for underprivileged children. Moreover, the deployment of cutting-edge technologies to enable the swift development of vaccines is propelling the market growth.

The development of innovative vaccines that can be delivered through micro patches to enable efficient vaccination in infants is anticipated to augment the market growth. Advancements in biotechnology and genetic engineering are expected to lead to the determination of accurate structures of antigens, hence aiding in the development of more efficient vaccines.  In addition, the increasing concerns regarding the resurgence of COVID-19 infections and the emergence of a novel virus are projected to propel the growth of the vaccine industry in the forecast period.

 

Key Industry Players in the United States Vaccine Market

The report presents a detailed analysis of the following key players in the United States vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca plc
  • Johnson & Johnson Services, Inc.
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Technology, Indication, End Use, Region
Breakup by Technology Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others
Breakup by Indication Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DPT), Polio, Hepatitis, Others
Breakup by End Use Paediatric Vaccine, Adult Vaccine, Travellers Vaccine
Breakup by Region New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, Far West
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca plc, Johnson & Johnson Services, Inc., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    United States
7    Industry Opportunities and Challenges
8    United States Vaccine Market Analysis

    8.1    Key Industry Highlights
    8.2    United States Vaccine Historical Market (2016-2020) 
    8.3    United States Vaccine Market Forecast (2021-2026)
    8.4    United States Vaccine Market by Technology
        8.4.1    Recombinant and Conjugate Vaccine
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    Inactivated Vaccines
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
        8.4.3    Live Attenuated Vaccines
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2016-2020)
            8.4.3.3    Forecast Trend (2021-2026)
        8.4.4    Toxoid Vaccines
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2016-2020)
            8.4.4.3    Forecast Trend (2021-2026)
        8.4.5    Others
    8.5    United States Vaccine Market by Indication
        8.5.1    Pneumococcal Disease
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2016-2020)
            8.5.1.3    Forecast Trend (2021-2026)
        8.5.2    Influenza
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2016-2020)
            8.5.2.3    Forecast Trend (2021-2026)
        8.5.3    Human Papilloma Virus
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2016-2020)
            8.5.3.3    Forecast Trend (2021-2026)
        8.5.4    Meningococcal Disease
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2016-2020)
            8.5.4.3    Forecast Trend (2021-2026)
        8.5.5    Rotavirus
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2016-2020)
            8.5.5.3    Forecast Trend (2021-2026)
        8.5.6    Varicella, Measles, Mumps, and Rubella
            8.5.6.1    Market Share
            8.5.6.2    Historical Trend (2016-2020)
            8.5.6.3    Forecast Trend (2021-2026)
        8.5.7    Diphtheria, Pertussis, and Tetanus (DPT)
            8.5.7.1    Market Share
            8.5.7.2    Historical Trend (2016-2020)
            8.5.7.3    Forecast Trend (2021-2026)
        8.5.8    Polio
            8.5.8.1    Market Share
            8.5.8.2    Historical Trend (2016-2020)
            8.5.8.3    Forecast Trend (2021-2026)
        8.5.9    Hepatitis
            8.5.9.1    Market Share
            8.5.9.2    Historical Trend (2016-2020)
            8.5.9.3    Forecast Trend (2021-2026)
        8.5.10    Others
    8.6    United States Vaccine Market by End Use
        8.6.1    Paediatric Vaccine
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2016-2020)
            8.6.1.3    Forecast Trend (2021-2026)
        8.6.2    Adult Vaccine
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2016-2020)
            8.6.2.3    Forecast Trend (2021-2026)
        8.6.3    Travellers Vaccine
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2016-2020)
            8.6.3.3    Forecast Trend (2021-2026)
    8.7    United States Vaccine Market by Region
        8.7.1    Market Share
            8.7.1.1    New England
            8.7.1.2    Mideast
            8.7.1.3    Great Lakes
            8.7.1.4    Plains
            8.7.1.5    Southeast
            8.7.1.6    Southwest
            8.7.1.7    Rocky Mountain
            8.7.1.8    Far West
9    Regional Analysis
    9.1    New England
        9.1.1    Historical Trend (2016-2020)
        9.1.2    Forecast Trend (2021-2026)
    9.2    Mideast
        9.2.1    Historical Trend (2016-2020)
        9.2.2    Forecast Trend (2021-2026)
    9.3    Great Lakes
        9.3.1    Historical Trend (2016-2020)
        9.3.2    Forecast Trend (2021-2026)
    9.4    Plains
        9.4.1    Historical Trend (2016-2020)
        9.4.2    Forecast Trend (2021-2026)
    9.5    Southeast
        9.5.1    Historical Trend (2016-2020)
        9.5.2    Forecast Trend (2021-2026)
    9.6    Southwest
        9.6.1    Historical Trend (2016-2020)
        9.6.2    Forecast Trend (2021-2026)
    9.7    Rocky Mountain
        9.7.1    Historical Trend (2016-2020)
        9.7.2    Forecast Trend (2021-2026)
    9.8    Far West
        9.8.1    Historical Trend (2016-2020)
        9.8.2    Forecast Trend (2021-2026)
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    GlaxoSmithKline plc
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Merck & Co., Inc. 
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    Novartis AG
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Pfizer Inc.    
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Sanofi    
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    AstraZeneca plc
            12.2.6.1    Company Overview
            12.2.6.2    Product Portfolio
            12.2.6.3    Demographic Reach and Achievements
            12.2.6.4    Certifications
        12.2.7    Johnson & Johnson Services, Inc.
            12.2.7.1    Company Overview
            12.2.7.2    Product Portfolio
            12.2.7.3    Demographic Reach and Achievements
            12.2.7.4    Certifications
        12.2.8    Others
13    Industry Events and Developments

 

List of Figures and Tables

1.    Market: Key Industry Highlights, 2016 and 2026
2.    United States Vaccine Historical Market: Breakup by Technology (USD Million), 2016-2020
3.    United States Vaccine Market Forecast: Breakup by Technology (USD Million), 2021-2026
4.    United States Vaccine Historical Market: Breakup by Indication (USD Million), 2016-2020
5.    United States Vaccine Market Forecast: Breakup by Indication (USD Million), 2021-2026
6.    United States Vaccine Historical Market: Breakup by End Use (USD Million), 2016-2020
7.    United States Vaccine Market Forecast: Breakup by End Use (USD Million), 2021-2026
8.    United States Vaccine Historical Market: Breakup by Region (USD Million), 2016-2020
9.    United States Vaccine Market Forecast: Breakup by Region (USD Million), 2021-2026
10.    United States Vaccine Market Structure

Key Questions Answered in the Report

In 2020, the United States vaccine market attained a value of nearly USD 11.2 billion.

The market is projected to grow at a CAGR of 9.8% between 2021 and 2026.

The market is being aided by the rising use of mRNA technology in vaccine development, the surge of the COVID-19 crisis, and the increasing approvals of the novel COVID-19 mRNA vaccines.

The industry is expected to be augmented by the rising demand for immunisation of infants, the deployment of cutting-edge technology in vaccine development, and advancements in biotechnology and genetic engineering.

The major regions in the industry are New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West.

The major technologies of vaccine in the industry are recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others.

The significant indications in the market are pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, and hepatitis, among others.

The various end uses of vaccines are paediatric vaccine, adult vaccine, and travellers vaccine.

The major players in the industry are GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca plc, and Johnson & Johnson Services, Inc., among others.

Analyst Review

The United States vaccine market attained a value of nearly USD 11.2 billion in 2020, driven by the rising use of mRNA technology in vaccine development. Aided by advancements in biotechnology and genetic engineering, the market is expected to witness a further growth in the forecast period of 2021-2026, growing at a CAGR of 9.8%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its technologies, the vaccine industry can be segmented into recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. On the basis of indication, the industry is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, and hepatitis, among others. By end use, the market is classified into paediatric vaccine, adult vaccine, and travellers vaccine. The major regional markets for vaccine in the United States are New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West. The key players in the above market include GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca plc, and Johnson & Johnson Services, Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER